DK0869784T3 - Hæmning af fedtsyresyntase som middel til formindskelse af adipocytmængden - Google Patents

Hæmning af fedtsyresyntase som middel til formindskelse af adipocytmængden

Info

Publication number
DK0869784T3
DK0869784T3 DK96939542T DK96939542T DK0869784T3 DK 0869784 T3 DK0869784 T3 DK 0869784T3 DK 96939542 T DK96939542 T DK 96939542T DK 96939542 T DK96939542 T DK 96939542T DK 0869784 T3 DK0869784 T3 DK 0869784T3
Authority
DK
Denmark
Prior art keywords
reduce
weight loss
complications
adipocyte
reduction
Prior art date
Application number
DK96939542T
Other languages
English (en)
Inventor
Francis P Kuhajda
Gary R Pasternack
Craig A Townsend
Neelakandha Mani
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of DK0869784T3 publication Critical patent/DK0869784T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK96939542T 1995-11-17 1996-11-15 Hæmning af fedtsyresyntase som middel til formindskelse af adipocytmængden DK0869784T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US694095P 1995-11-17 1995-11-17

Publications (1)

Publication Number Publication Date
DK0869784T3 true DK0869784T3 (da) 2006-01-16

Family

ID=21723376

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96939542T DK0869784T3 (da) 1995-11-17 1996-11-15 Hæmning af fedtsyresyntase som middel til formindskelse af adipocytmængden

Country Status (7)

Country Link
EP (1) EP0869784B1 (da)
AT (1) ATE303144T1 (da)
AU (1) AU7668596A (da)
DE (1) DE69635130T2 (da)
DK (1) DK0869784T3 (da)
ES (1) ES2251002T3 (da)
WO (1) WO1997018806A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
CA2450660C (en) 2001-06-13 2011-08-16 Magnachem International Laboratories, Inc. Lactone formulations and method of use
US8188145B2 (en) 2002-06-12 2012-05-29 Magnachem International Laboratories, Inc. Synthetic lactone formulations and method of use
BRPI0312413A2 (pt) * 2002-07-01 2016-08-02 Fasgen Llc compostos, composições farmacêuticas contendo os mesmos, e método de utilização para os mesmos
JP5616220B2 (ja) 2007-06-01 2014-10-29 ザ トラスティーズ オブ プリンストン ユニバーシティ 宿主細胞代謝経路の調節によるウイルス感染治療
CN102265154A (zh) 2008-10-24 2011-11-30 马格纳化学国际实验室公司 用于筛选与rad9选择性相互作用的化合物的方法
WO2010118324A2 (en) 2009-04-09 2010-10-14 Nuclea Biotechnologies, LLC Antibodies against fatty acid synthase
AU2014249003A1 (en) 2013-03-13 2015-10-15 Forma Therapeutics, Inc. Novel compounds and compositions for inhibition of FASN

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4028397A (en) * 1973-07-05 1977-06-07 Hoffmann-La Roche Inc. Hydroxycitric acid derivatives
US4218443A (en) * 1979-01-15 1980-08-19 Hoffmann-La Roche Inc. Polyether ionophores as antiobesity and hypotriglyceridemic agents
US5246960A (en) * 1984-12-21 1993-09-21 Hoffmann-La Roche Inc. Oxetanones
JP2746372B2 (ja) * 1988-03-11 1998-05-06 科研製薬株式会社 Ｆ−０３６８物質
GB9209628D0 (en) * 1992-05-05 1992-06-17 Smithkline Beecham Plc Compounds
MX9304501A (es) * 1992-07-24 1994-04-29 Univ Johns Hopkins Quimioterapia para cancer.

Also Published As

Publication number Publication date
EP0869784A4 (en) 2001-02-07
EP0869784B1 (en) 2005-08-31
WO1997018806A1 (en) 1997-05-29
AU7668596A (en) 1997-06-11
ATE303144T1 (de) 2005-09-15
DE69635130T2 (de) 2006-06-14
DE69635130D1 (de) 2005-10-06
ES2251002T3 (es) 2006-04-16
EP0869784A1 (en) 1998-10-14

Similar Documents

Publication Publication Date Title
Morrow et al. Formation of novel non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in carbon tetrachloride hepatotoxicity. An animal model of lipid peroxidation.
Sugimura Studies on environmental chemical carcinogenesis in Japan
Yin et al. Carbonyl toxification hypothesis of biological aging
Reiterer et al. Zinc deficiency increases plasma lipids and atherosclerotic markers in LDL-receptor–deficient mice
DK0869784T3 (da) Hæmning af fedtsyresyntase som middel til formindskelse af adipocytmængden
AP2002002634A0 (en) Malonamic Acids And Derivatives Thereof As Thyroid Receptor Ligands.
AR022204A1 (es) Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende.
Ashraf et al. Endothelium mediated vasorelaxant response of garlic in isolated rat aorta: role of nitric oxide
DK0539448T3 (da) Levnedsmiddelsammensætninger og farmaceutiske sammensætninger indeholdende kortkædede, monoumættede fedtsyrer og fremgangsmåde til anvendelse
ATE129152T1 (de) Zusammensetzungen von maillard-reaktion inhibitoren.
Shih et al. Concentration-dependent differential effects of quercetin on rat aortic smooth muscle cells
Cherian Effect of papaya latex extract on gravid and non-gravid rat uterine preparations in vitro
AU690853B2 (en) Peptide for inhibiting blood triglyceride level rise and inhibitor for blood triglyceride level rise comprising the peptide as active ingredient
AU6667001A (en) Novel heterocyclic analogs of diphenylethylene compounds
JPH07223941A (ja) 抗補体作用物質
TW200513194A (en) Fat and oil processed composition for prevention and/or amelioration of life-style related disease
KR100437274B1 (ko) 연골재생제로서 아피제닌을 함유하는 골관절염 치료 조성물
PT966283E (pt) Produtos farmaceuticos para cura e prevencao de doencas resultantes de lesao das celulas do endotelio vascular
Soengas et al. Effects of cortisol and thyroid hormone treatment on the glycogen metabolism of selected tissues of domesticated rainbow trout, Oncorhynchus mykiss
Turner Garlic and circulatory disorders
AU2003283227A1 (en) Method and means for the treatment of vascular and cardiac diseases
Gillman et al. A simple dietary technique for the production of hepatic necrosis with a consideration of the factors preventing the lesion
ROBERT Complete prevention of cerebral accidents in malignant hypertension
Fabricio Main resveratrol action mechanisms in postmenopausal osteoporosis
NAGATA et al. Effect of ascorbic acid 2-O-α-glucoside on hydrocortisone-induced cataract formation in developing chick embryos: II. Influence on glutathione and lipid peroxide contents in the lens